Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your doctor expects you to live at least 12 more weeks.
- You have at least one tumor that can be measured on a scan.
- Your cancer has gotten worse after one or two prior treatments for ES-SCLC.
- You have not taken any drug that blocks the VEGF or VEGFR pathway (like avastin, apatinib, or other similar medicines) before.
- You do not have an active infection or need antibiotics within the last 2 weeks, and you can swallow pills without trouble.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (apatinib, adebrelimab, and EC chemotherapy) as the first treatment for extensive-stage small cell lung cancer that has spread. The goal is to see if this combination works better than standard treatments alone.
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.